104433SPX - Novel Mastitis TreatmentClosedFeasibility StudiesInnovate UKBiovorn Ltd, an innovative UK biotechnology company, is developing a novel anti-microbial ("SPX") to treat mastitis in livestock, helping farmers to improve productivity and livestock welfare whilst reducing the need for antibiotics and negative side-effects associated with current treatments.The proposed project will allow Biovorn to further investigate the effectiveness of SPX and to evaluate potential commercialisation options.